A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.

Vanderbilt investigators have demonstrated that a certain protein complex drives tumor progression in aggressive breast cancers.

Signaling by a receptor that is overexpressed in aggressive forms of breast cancer has been linked to glutamine metabolism, suggesting new anti-cancer therapeutic targets.

Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.

A specific gene expression profile represents a novel, biologically relevant “signature” for identifying colon cancers with high risk of metastatic recurrence, Vanderbilt researchers have found.

Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.